News Conference News VIVA 2024 DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years L.A. McKeown November 11, 2024
News Conference News VIVA 2024 Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK L.A. McKeown November 05, 2024
News Conference News VIVA 2022 TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years L.A. McKeown November 03, 2022
News Conference News VIVA 2021 EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions L.A. McKeown October 12, 2021
News Conference News VIVA 2021 Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI L.A. McKeown October 08, 2021
News Conference News VIVA 2020 As ‘Paclitaxelgate’ Loses Steam, Experts Mull Lasting Impact for Future Trials, Practice L.A. McKeown November 27, 2020
News Conference News VIVA 2020 BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia L.A. McKeown November 11, 2020
News Conference News VIVA 2020 DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD L.A. McKeown November 09, 2020
News Conference News VIVA 2019 Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions L.A. McKeown November 13, 2019
News Conference News VIVA 2019 Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee? L.A. McKeown November 06, 2019
News Conference News VIVA 2018 Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease L.A. McKeown November 15, 2018
News Conference News VIVA 2018 IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions L.A. McKeown November 06, 2018
Presentation VIVA 2017 Paclitaxel-Eluting Stent Treatment for PAD: Insights from the Zilver PTX Post-Market Study in Japan Presenter: Michael Dake September 14, 2017
News Conference News VIVA 2017 DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease L.A. McKeown September 13, 2017
News Conference News VIVA 2016 Longer Term, IN.PACT SFA Trial and Global Registry Continue to Support DCB Therapy as an Option L.A. McKeown October 12, 2016
News Conference News VIVA 2016 Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear L.A. McKeown September 21, 2016
News Conference News VIVA 2016 Positive Results Continue at 2 Years for Paclitaxel-Eluting PAD Stent L.A. McKeown September 20, 2016